Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to -$501000.0.

  • Verrica Pharmaceuticals' Change in Accured Expenses fell 15591.52% to -$501000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.1 million, marking a year-over-year decrease of 16087.35%. This contributed to the annual value of -$294000.0 for FY2024, which is 10260.38% down from last year.
  • According to the latest figures from Q3 2025, Verrica Pharmaceuticals' Change in Accured Expenses is -$501000.0, which was down 15591.52% from -$1.4 million recorded in Q2 2025.
  • Verrica Pharmaceuticals' 5-year Change in Accured Expenses high stood at $5.5 million for Q3 2023, and its period low was -$5.2 million during Q4 2024.
  • In the last 5 years, Verrica Pharmaceuticals' Change in Accured Expenses had a median value of $545000.0 in 2022 and averaged $528368.4.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 58181.82% in 2022, then skyrocketed by 701111.11% in 2023.
  • Verrica Pharmaceuticals' Change in Accured Expenses (Quarter) stood at -$700000.0 in 2021, then surged by 110.29% to $72000.0 in 2022, then skyrocketed by 7011.11% to $5.1 million in 2023, then crashed by 201.17% to -$5.2 million in 2024, then soared by 90.33% to -$501000.0 in 2025.
  • Its Change in Accured Expenses was -$501000.0 in Q3 2025, compared to -$1.4 million in Q2 2025 and $973000.0 in Q1 2025.